RT Journal Article
SR Electronic
T1 Quantifying the dynamics of COVID-19 burden and impact of interventions in Java, Indonesia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20198663
DO 10.1101/2020.10.02.20198663
A1 Djaafara, Bimandra A
A1 Whittaker, Charles
A1 Watson, Oliver J
A1 Verity, Robert
A1 Brazeau, Nicholas F
A1 Widyastuti,
A1 Oktavia, Dwi
A1 Adrian, Verry
A1 Salama, Ngabila
A1 Bhatia, Sangeeta
A1 Nouvellet, Pierre
A1 Sherrard-Smith, Ellie
A1 Churcher, Thomas S
A1 Surendra, Henry
A1 Lina, Rosa N
A1 Ekawati, Lenny L
A1 Lestari, Karina D
A1 Andrianto, Adhi
A1 Thwaites, Guy
A1 Baird, J Kevin
A1 Ghani, Azra C
A1 Elyazar, Iqbal RF
A1 Walker, Patrick GT
YR 2020
UL http://medrxiv.org/content/early/2020/10/02/2020.10.02.20198663.abstract
AB Measuring COVID-19 spread remains challenging in many countries due to testing limitations. In Java, reported cases and deaths increased throughout 2020 despite intensive control measures, particularly within Jakarta and during Ramadan. However, underlying trends are likely obscured by variations in case ascertainment. COVID-19 protocol funerals in Jakarta provide alternative data indicating a substantially higher burden than observed within confirmed deaths. Transmission estimates using this metric follow mobility trends, suggesting earlier and more sustained intervention impact than observed in routine data. Modelling suggests interventions have lessened spread to rural, older communities with weaker healthcare systems, though predict healthcare capacity will soon be exceeded in much of Java without further control. Our results highlight the important role syndrome-based measures of mortality can play in understanding COVID-19 transmission and burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Centre funding from the UK Medical Research Council under a concordat with the UK Foreign, Commonwealth and Development Office and the Wellcome Trust, also under a concordat with the UK Foreign, Commonwealth and Development Office. BAD acknowledges a matched MRC Centre 1+3 studentship funding by Imperial College London School of Public Health. IRFE acknowledges a funding from Oxford University Clinical Reseach Unit (OUCRU) Strategic Committee Research for COVID-19, Vietnam. JKB, IRFE, LLE, KDL, RNL, AA, HS are supported by the Wellcome Trust, UK (106680/Z/14/Z). GT is supported by the Wellcome Trust, UK (110179/Z/15/Z). CW acknowledges funding from a UK Medical Research Council Doctoral Training Partnership (DTP) studentship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approvals necessaryAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used are publicly available from these websites: 1. https://corona.jakarta.go.id/id/data-pemantauan 2. https://covid19.go.id/peta-sebaran 3. http://kcov.id/daftarpositif 4. https://www.who.int/indonesia/news/novel-coronavirus/situation-reports